


NEW SYNTHESIS OF THE NOVEL IMMUNOACTIVATOR FR900483

Sui-Hui Chen and Samuel J. Danishefsky
Department of Chemistry, Yale University, New Haven, CT 06511-8118

Summary: Syntheses of the title compound from D-glucal or D-arabinose are reported.

Recently Shibata et. al. described the isolation of metabolite, FR-900483 from the fungus *Nectria lucidia* 4490-1.² The compound was shown to have the structure 1. A novel kind of biological activity was reported for this substance. A factor isolated from the sera of sarcoma 180 bearing mice has the capacity to inhibit concanavalin A induced lymphocyte production. FR-900483 suppresses this inhibition. It also suppresses similar inhibition occasioned by mitomycin C.


As part of the studies leading to the determination of its structure, FR-900483 was synthesized from a glucose derivative, 2.² Raney Nickel reduction of oxime 2 provided the 5-amino system, 3. Excision of C₁ was used in generating a synthetic equivalent of the formal aminoaldehyde 4 en route to 1.



Our interest in applications of the Vasella reaction^{3,4} prompted a different proposal for synthesizing 1. In this alternative view, C₅ of the glucose precursor would emerge as C₁ of compound 1 and C₂ would become C₄. The stereochemistry of C₄ would be controlled by displacement of a leaving group at C₂ of the pyranose by a nitrogen based nucleophile. A


Vasella reaction would be used to pave the way for excising C₆ of the glucose and converting C₅ to the aldehyde level of oxidation. This approach is summarized in Scheme II.

SCHEME II




Glycal **6** was prepared from D-glucal (40% overall) by mono silylation (TBS Cl/imidazole) and di-benzylation (NaH; BnBr). Reaction of **6** with MCPBA in methanol⁶ followed by disilylation (TBAF-THF) and thence by selective bromination (Ph₃P/CBr₄),⁷ afforded compound **7**. Protection of the hydroxyl function with TBSCl-imidazole gave the ether **8** (50-60% from **6**). Treatment of the latter with zinc in aqueous ethanol³ afforded **9** in 75% yield. Reduction of **1** with sodium borohydride gave rise to **10** the product of silyl transfer, in 76% yield. Inversion at C₂ was accomplished (40-45% overall) by triflylation followed by azidolysis (sodium azide, DMF rt.). Ozonolysis (O₃-CH₂Cl₂ -78°) of **11** gave **12** which, upon de-silylation and acetylation gave the pyranosyl acetate **13** in 80% yield. Reduction of the latter (H₂/Pd/Al₂O₃) followed by acylation with trifluoroacetic anhydride afforded a quantitative yield of **14**. Finally, debenzylation (Pearlman's catalyst)⁸ followed by sequential treatment with 1N sodium hydroxide and Dowex acidic resin afforded FR900483⁹ in high yield.

SCHEME III



Although this route did demonstrate some of the potentialities of the Vasella reaction,³ the importance of the goal system prompted us to evaluate an alternate route which turned out to be shorter and more efficient. This route started with **15**¹⁰ derived from D-arabinose. Benzoylation (BnBr; Ag₂O) afforded **16**. After cleavage of the acetonide (H₂SO₄; acetone - water) diol **17** was obtained (65% overall). Preferential (4:1) benzoylation at the C₃, rather than the C₄ alcohol via the stannylidene method¹¹ ((i) nBu₂SnO; (ii) CsF/BnBr DMF) afforded **18** (70%). Inversion of configuration at the C₄ hydroxyl ((i) EtO₂CN = NCO₂Et Ph₃P; benzoic acid;¹² (ii) NaOMe/MeOH) gave rise to **19** (55% overall). Triflylation (Tf₂O; Py) and azidolysis (NaN₃/DMF) led to **20** which upon acetolysis¹³ at C₁ (conc H₂SO₄; Ac₂O) afforded **14** (65% overall) and thence, as above, FR 900483.

SCHEME IV



In summary, new routes to **1** via D-glucal and D-arabinose have been developed. These pathways produce various synthetic intermediates which may be helpful in evaluating structure activity relationships of this novel immunomodulator.

Acknowledgments. This work was supported by PHS Grant AI16943. A Department of Education Fellowship from the People's Republic of China to S.-H. C. is gratefully acknowledged. NMR spectra were obtained through the auspices of the Northeast Regional NSF/NMR Facility at Yale University, which is supported by NSF Chemistry Division Grant CHE 7916210.

References and Notes

1. Shibata, T.; Nakayama, O.; Tsurimi, Y.; Okuhara, M.; Terano, H.; Kohsaka, M. *J. of Antibiot.* **1988**, *41*, 296.
2. Kayakiri, H.; Takare, H.; Shighiro, T.; Setor, H.; Uchida, I.; Terano, H.; Hashimoto, M. *Tetrahedron Lett.* **1988**, *29*, 1725.
3. For some striking examples of the Vasella reaction, see: (a) Bernet, B.; Vasella, A. *Helvetica Chimica Acta* **1979**, *62*, 2400. (b) Bernet, B.; Vasella, A. *Helvetica Chimica Acta* **1984**, *67*, 1328.

4. The Vasella reaction was used at two stages in a recent synthesis of FK506 accomplished in our laboratory. (a) Villalobos, A.; Danishefsky, S. J. *J. Org. Chem.* In Press. (b) Jones, A. B.; R. G. Linde II; Coleman, R. S.; Danishefsky, S. J. *J. Org. Chem.* In Press.
5. Blackburne, I. D.; Fredericks, P. M.; Guthrie, R. D. *Aust. J. Chem.* **1976**, *29*, 381.
6. cf. Sweet, F.; Brown, R. K. *Can. J. Chem.* **1966**, *44*, 1571.
7. Castro, B. C. R.; *Organic Reactions* **1983**, *29*.
8. Pearlman, W. M. *Tetrahedron Lett.* **1967**, *10*, 1663.
9. The proton (250 MHz) and ¹³C spectra NMR of synthetic FR900483 as well as the chromatographic mobilities in two solvent systems agree very closely with reported values. A sample of the compound was not available from Fujisawa.
10. Fletcher, H. G., Jr. *Methods in Carb. Chem. Vol II*, 386.
11. For related cases, see: (a) Ogawa, T.; Matsui, M. *Tetrahedron* **1981**, *37*, 2363. (b) David, S.; Hanessian, S. *Tetrahedron* **1985**, *41*, 643.
12. cf. Mitsunobu, O. *Synthesis* **1981**, *1*.
13. Biermann, C. J. *Advances in Carbohydr. Chem. and Biochem.* **1988**, *46*, 251.

(Received in USA 31 January 1990)